
Opinion|Videos|December 5, 2025
Introductions
Panelists introduce key CDK4/6 inhibitor data from ESMO 2025, setting the stage for insightful discussions on pivotal clinical trials and questions.
Advertisement
Episodes in this series
In this opening segment, the panelists introduce themselves and set the stage for the series, outlining the purpose of the discussion and the key CDK4/6 inhibitor data featured at ESMO 2025. Viewers are oriented to the trials that will anchor the conversation and the clinical questions the experts aim to explore throughout the program.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
The Biosimilar Conversation Nobody Is Having at the Pharmacy Counter: Why Adoption Is Still Struggling and What We Can Do About It
2
Medicare Is Finally Covering GLP-1s for Weight Loss: What the Bridge Program Means for Your Practice
3
FDA Narrows Compounding Rules for GLP-1s: How Pharmacists Should Respond
4
Updated 2025-2026 COVID-19 Vaccine Nearly Halved ED Visits, Hospitalizations in CDC-Funded Study
5

















































































































